Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma

Swathi Ramakrishnan, Roberto Pili

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Recent investigations of renal cell carcinoma (RCC) have revealed several epigenetic modifications, as well as alterations in the genes and enzymes that regulate these changes. Preclinical models have revealed that histone gene modifiers and epigenetic alterations may play a critical role in RCC tumorigenesis. Specific changes in DNA methylation and mutations of histone modifiers have been identified and may be associated with an aggressive phenotype. In addition, the potential of reversing the effects of these enzymes and hence reversing the cellular epigenetic landscape to a "normal phenotype" have led to an increasing interest in developing targeted chromatin remodeling agents. However, the translation of the understanding of these changes to the clinic for the treatment of RCC has posed significant challenges, partly due to tumor heterogeneity. This review describes the aberrant histone and DNA alterations recently reported in RCC and highlights the potential targeted chromatin remodeling therapies in the management of this disease.

Original languageEnglish (US)
Pages (from-to)333-340
Number of pages8
JournalCancer Journal (United States)
Volume19
Issue number4
DOIs
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Renal Cell Carcinoma
Epigenomics
Histones
Chromatin Assembly and Disassembly
Modifier Genes
Phenotype
DNA Methylation
Enzymes
Disease Management
Carcinogenesis
Mutation
DNA
Genes
Neoplasms
Therapeutics

Keywords

  • epigenetic alterations
  • histone modifiers
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. / Ramakrishnan, Swathi; Pili, Roberto.

In: Cancer Journal (United States), Vol. 19, No. 4, 07.2013, p. 333-340.

Research output: Contribution to journalReview article

@article{222dc08ab67941d58592645c72a5450e,
title = "Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma",
abstract = "Recent investigations of renal cell carcinoma (RCC) have revealed several epigenetic modifications, as well as alterations in the genes and enzymes that regulate these changes. Preclinical models have revealed that histone gene modifiers and epigenetic alterations may play a critical role in RCC tumorigenesis. Specific changes in DNA methylation and mutations of histone modifiers have been identified and may be associated with an aggressive phenotype. In addition, the potential of reversing the effects of these enzymes and hence reversing the cellular epigenetic landscape to a {"}normal phenotype{"} have led to an increasing interest in developing targeted chromatin remodeling agents. However, the translation of the understanding of these changes to the clinic for the treatment of RCC has posed significant challenges, partly due to tumor heterogeneity. This review describes the aberrant histone and DNA alterations recently reported in RCC and highlights the potential targeted chromatin remodeling therapies in the management of this disease.",
keywords = "epigenetic alterations, histone modifiers, Renal cell carcinoma",
author = "Swathi Ramakrishnan and Roberto Pili",
year = "2013",
month = "7",
doi = "10.1097/PPO.0b013e3182a09e07",
language = "English (US)",
volume = "19",
pages = "333--340",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma

AU - Ramakrishnan, Swathi

AU - Pili, Roberto

PY - 2013/7

Y1 - 2013/7

N2 - Recent investigations of renal cell carcinoma (RCC) have revealed several epigenetic modifications, as well as alterations in the genes and enzymes that regulate these changes. Preclinical models have revealed that histone gene modifiers and epigenetic alterations may play a critical role in RCC tumorigenesis. Specific changes in DNA methylation and mutations of histone modifiers have been identified and may be associated with an aggressive phenotype. In addition, the potential of reversing the effects of these enzymes and hence reversing the cellular epigenetic landscape to a "normal phenotype" have led to an increasing interest in developing targeted chromatin remodeling agents. However, the translation of the understanding of these changes to the clinic for the treatment of RCC has posed significant challenges, partly due to tumor heterogeneity. This review describes the aberrant histone and DNA alterations recently reported in RCC and highlights the potential targeted chromatin remodeling therapies in the management of this disease.

AB - Recent investigations of renal cell carcinoma (RCC) have revealed several epigenetic modifications, as well as alterations in the genes and enzymes that regulate these changes. Preclinical models have revealed that histone gene modifiers and epigenetic alterations may play a critical role in RCC tumorigenesis. Specific changes in DNA methylation and mutations of histone modifiers have been identified and may be associated with an aggressive phenotype. In addition, the potential of reversing the effects of these enzymes and hence reversing the cellular epigenetic landscape to a "normal phenotype" have led to an increasing interest in developing targeted chromatin remodeling agents. However, the translation of the understanding of these changes to the clinic for the treatment of RCC has posed significant challenges, partly due to tumor heterogeneity. This review describes the aberrant histone and DNA alterations recently reported in RCC and highlights the potential targeted chromatin remodeling therapies in the management of this disease.

KW - epigenetic alterations

KW - histone modifiers

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84880954189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880954189&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e3182a09e07

DO - 10.1097/PPO.0b013e3182a09e07

M3 - Review article

C2 - 23867515

AN - SCOPUS:84880954189

VL - 19

SP - 333

EP - 340

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 4

ER -